Oncology Outcomes Research Initiative, University of Calgary, Calgary, AB, Canada; Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Department of Medical Oncology and Hematology, Cross Cancer Institute, Edmonton, AB, Canada.
Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e277-e285. doi: 10.1016/j.clml.2023.05.013. Epub 2023 May 29.
The Follicular lymphoma international prognostic index (FLIPI) risk score and POD24 have previously been shown to have prognostic value in follicular lymphoma (FL), but the extent to which they can inform prognosis at the time of subsequent relapse is uncertain.
We conducted a longitudinal cohort study of individuals diagnosed with FL between 2004 and 2010 in Alberta, Canada who received front-line therapy and subsequently relapsed. FLIPI covariates were measured prior to the initiation of front-line therapy. Median overall survival (OS), progression-free survival (PFS2), and time to next treatment (TTNT2) were estimated from the time of relapse.
A total of 216 individuals were included. The FLIPI risk score was highly prognostic at the time of relapse for OS (c-statistic = 0.70; HR = 7.38; 95% CI: 3.05-17.88), PFS2 (c-statistic = 0.68; HR = 5.84; 95% CI: 2.93-11.62) and TTNT2 (c-statistic = 0.68; HR = 5.72; 95% CI: 2.87-11.41). POD24 was not prognostic at the time of relapse for either OS, PFS2, or TTNT2 (c-statistic = 0.55).
The FLIPI score measured at diagnosis may help with the risk stratification of individuals with relapsed FL.
滤泡性淋巴瘤国际预后指数（FLIPI）风险评分和 POD24 先前已被证明在滤泡性淋巴瘤（FL）中具有预后价值，但它们在随后复发时能在多大程度上提供预后信息尚不确定。
我们对 2004 年至 2010 年间在加拿大艾伯塔省诊断为 FL 并接受一线治疗后复发的患者进行了一项纵向队列研究。FLIPI 协变量在一线治疗开始前进行测量。从复发时起，估计总生存期（OS）、无进展生存期（PFS2）和下一次治疗时间（TTNT2）的中位数。
共纳入 216 例患者。FLIPI 风险评分在复发时对 OS（c 统计量=0.70；HR=7.38；95%CI：3.05-17.88）、PFS2（c 统计量=0.68；HR=5.84；95%CI：2.93-11.62）和 TTNT2（c 统计量=0.68；HR=5.72；95%CI：2.87-11.41）具有高度预后价值。POD24 在复发时对 OS、PFS2 或 TTNT2 均无预后价值（c 统计量=0.55）。
诊断时测量的 FLIPI 评分可能有助于对复发 FL 患者进行风险分层。
